Welcome!

News Feed Item

BD Announces Results For 2014 First Fiscal Quarter

-- Raises the bottom end of full fiscal year 2014 revenue and earnings ranges for guidance.

FRANKLIN LAKES, N.J., Feb. 4, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the first fiscal quarter ended December 31, 2013, representing an increase of 6.0 percent from the prior-year period, or 6.7 percent on a foreign currency-neutral basis. Revenue growth was aided, in part, by favorable timing of orders in the BD Medical and BD Diagnostics segments.

"Fiscal year 2014 is off to a strong start," said Vincent A. Forlenza, Chairman, CEO and President. "Our revenue and earnings growth exceeded our expectations and we have continuing confidence that we have built a solid foundation for future growth. Accordingly, we are raising the bottom end of our previous revenue and earnings ranges for our full fiscal year guidance."

First Quarter Earnings
Reported diluted earnings per share from continuing operations for the first quarter were $1.37 compared with $1.35 in the prior-year period, representing a 1.5 percent increase. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the first quarter increased by 8.1 percent. Adjusted diluted earnings per share from continuing operations excluding the medical device excise tax, which went into effect in January 2013 under the U.S. healthcare reform law, were $1.42, or an increase of 11.9 percent.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.06 billion, representing an increase of 8.2 percent compared with the prior-year period, or an increase of 8.6 percent on a foreign currency-neutral basis. The segment's revenue growth reflects strong sales in the Medical Surgical Systems and Diabetes Care units and solid sales in the Pharmaceutical Systems unit. Both the Medical Surgical and Pharmaceutical Systems units also benefitted from favorable timing of orders.

In the BD Diagnostics segment, worldwide revenues for the quarter were $672 million, representing an increase of 3.1 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. The segment's growth was driven by international expansion in both the Preanalytical Systems and Diagnostic Systems business units. Diagnostic systems growth was also aided, in part, from a timing of flu orders.

In the BD Biosciences segment, worldwide revenues for the quarter were $279 million, representing an increase of 5.4 percent compared with the prior-year period, or an increase of 5.7 percent on a foreign currency-neutral basis. The segment's growth was driven by continued strength in emerging markets, clinical reagents sales and solid instrument placements in both the U.S. and Western Europe.

Geographic Results
First quarter revenues in the U.S. of $849 million represent an increase of 2.3 percent over the prior-year period. Revenues outside of the U.S. were $1.17 billion, representing an increase of 8.9 percent compared with the prior-year period, or an increase of 10.0 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and sales of safety-engineered products in addition to solid growth in Western Europe.

Fiscal 2014 Outlook for Full Year
The Company estimates that reported and currency-neutral revenues for the full fiscal year 2014 will increase 4.5 to 5.0 percent. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2014 to be between $6.19 and $6.22, which represents growth of 6.5 to 7.0 percent over 2013 adjusted diluted earnings per share of $5.81.  On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 9.0 to 9.5 percent, or 9.5 to 10.0 percent excluding the incremental impact of the medical device tax.  The Company plans to repurchase, subject to market conditions, about $450 million of its common stock in fiscal year 2014.

Conference Call Information
A conference call regarding BD's first quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, February 4th, 2014.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, February 11, 2014, confirmation number 31318159.

Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.  Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers.  Percentages and earnings per share amounts presented are calculated from the underlying whole-dollar amounts.

About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2014 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors; pricing and market pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Alyssa J. Zeff, Corporate Communications – 201-847-4358

 

BECTON DICKINSON AND COMPANY


CONSOLIDATED INCOME STATEMENTS


(Unaudited; Amounts in millions, except share and per share data)











Three Months Ended December 31,



2013


2012


% Change










REVENUES

$

2,015

$

1,900


6.0










Cost of products sold


980


894


9.6


Selling and administrative 


531


496


7.1


Research and development


126


118


6.4


TOTAL OPERATING COSTS








     AND EXPENSES


1,637


1,508


8.5










OPERATING INCOME


378


392


(3.6)










Interest income


14


8


75.7


Interest expense


(34)


(35)


(4.3)


Other income, net


1


1


(14.0)










INCOME FROM CONTINUING OPERATIONS BEFORE








     INCOME TAXES


359


366


(1.9)










Income tax provision


88


95


(8.3)










INCOME FROM CONTINUING OPERATIONS


271


270


0.4










INCOME FROM DISCONTINUED OPERATIONS








   NET OF INCOME TAX PROVISION OF








   $0 AND $216, RESPECTIVELY


-


355


        NM 










NET INCOME

$

271

$

625


(56.6)










EARNINGS PER SHARE
















Basic:








Income from continuing operations

$

1.40

$

1.38


1.4


Income from discontinued operations

$

-

$

1.81


        NM 


Net income 

$

1.40

$

3.18


(56.0)










Diluted:








Income from continuing operations

$

1.37

$

1.35


1.5


Income from discontinued operations

$

-

$

1.78


        NM 


Net income 

$

1.37

$

3.13


(56.2)


















AVERAGE SHARES OUTSTANDING (in thousands)
















     Basic


194,203


196,427




     Diluted


198,110


199,570












NM - Not Meaningful








 

BECTON DICKINSON AND COMPANY


SUPPLEMENTAL REVENUE INFORMATION


REVENUES BY SEGMENT AND GEOGRAPHIC AREA


(Unaudited; Amounts in millions)











Three Months Ended December 31,



2013


2012


% Change










BD MEDICAL








   United States

$

441

$

425


3.8


   International


622


558


11.5


TOTAL

$

1,064

$

983


8.2










BD DIAGNOSTICS








   United States

$

321

$

321


0.1


   International


351


331


6.0


TOTAL

$

672

$

652


3.1










BD BIOSCIENCES








   United States

$

87

$

84


3.3


   International


192


181


6.3


TOTAL

$

279

$

265


5.4










TOTAL REVENUES








   United States

$

849

$

830


2.3


   International


1,166


1,070


8.9


TOTAL

$

2,015

$

1,900


6.0


 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31,

(Unaudited; Amounts in millions)









United States



2013


2012


 % Change 








BD MEDICAL







   Medical Surgical Systems

$

262

$

249


5.3

   Diabetes Care


122


112


8.4

   Pharmaceutical Systems


57


64


(10.4)

TOTAL

$

441

$

425


3.8








BD DIAGNOSTICS







   Preanalytical Systems

$

171

$

167


2.7

   Diagnostic Systems


149


154


(2.7)

TOTAL

$

321

$

321


0.1








BD BIOSCIENCES

$

87

$

84


3.3








TOTAL UNITED STATES

$

849

$

830


2.3

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)













International







 % Change 



2013


2012


 Reported 


FXN


FX Impact












BD MEDICAL











   Medical Surgical Systems

$

317

$

287


10.4


12.4


(2.0)

   Diabetes Care


142


130


8.7


11.5


(2.8)

   Pharmaceutical Systems


164


141


16.4


12.6


3.8

TOTAL

$

622

$

558


11.5


12.2


(0.7)












BD DIAGNOSTICS











   Preanalytical Systems

$

176

$

168


4.8


6.1


(1.3)

   Diagnostic Systems


175


164


7.2


10.2


(3.0)

TOTAL

$

351

$

331


6.0


8.1


(2.1)












BD BIOSCIENCES

$

192

$

181


6.3


6.8


(0.5)












TOTAL INTERNATIONAL

$

1,166

$

1,070


8.9


10.0


(1.1)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)













Total







 % Change 



2013


2012


 Reported 


FXN


FX Impact












BD MEDICAL 











   Medical Surgical Systems

$

579

$

536


8.0


9.1


(1.1)

   Diabetes Care


264


243


8.6


10.1


(1.5)

   Pharmaceutical Systems


221


205


8.0


5.5


2.5

TOTAL

$

1,064

$

983


8.2


8.6


(0.4)












BD DIAGNOSTICS











   Preanalytical Systems

$

347

$

335


3.7


4.4


(0.7)

   Diagnostic Systems


325


317


2.4


3.9


(1.5)

TOTAL

$

672

$

652


3.1


4.2


(1.1)












BD BIOSCIENCES

$

279

$

265


5.4


5.7


(0.3)












TOTAL REVENUES

$

2,015

$

1,900


6.0


6.7


(0.7)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

SAFETY REVENUES

(Unaudited; Amounts in millions)













Three Months Ended December 31,







 % Change 



2013


2012


 Reported 


FXN


FX Impact












TOTAL SAFETY REVENUES











   United States

$

315

$

291


8.1


8.1


-

   International


242


220


10.1


12.0


(1.9)

TOTAL

$

557

$

511


9.0


9.8


(0.8)












BY SEGMENT











   BD Medical

$

285

$

252


13.0


14.0


(1.0)

   BD Diagnostics


272


259


5.0


5.7


(0.7)

TOTAL

$

557

$

511


9.0


9.8


(0.8)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures

(Unaudited)

















Three Months Ended December 31,



2013


2012


Growth


Foreign Currency Translation


Foreign Currency Neutral Change


Growth %


Foreign Currency Neutral Growth %
















Reported Diluted Earnings per Share from Continuing Operations

$

1.37

$

1.35

$

0.02

$

(0.09)

$

0.11


1.5%


8.1%
















Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act
($14 million or $9 million after-tax)


0.05


0.00


























Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax

$

1.42

$

1.35

$

0.07

$

(0.09)

$

0.16


5.2%


11.9%

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Outlook Reconciliation










Reported







Basis


FX Impact


FXN Basis








Revenues - Full Year 2014 estimated growth


4.5% - 5.0%


0.0%


4.5% - 5.0%













































Full Year


Full Year





2014


2013


% Increase



(estimated)





Reported Fully Diluted Earnings per Share 







from Continuing Operations

$

6.19 - 6.22

$

4.67


NM








Pending Litigation Settlement (1)




0.07










Verdict Charge (2)




1.06










Pension Settlement Charge (3)




0.02










Adjusted Fully Diluted Earnings per Share 







from Continuing Operations

$

6.19 - 6.22

$

5.81


6.5% - 7.0%








FX Impact






(2.5%)








Adjusted FXN Growth






9.0% - 9.5%








Medical Device Excise Tax Impact (4)






(0.5%)








Adjusted FXN Growth (excluding the medical device excise tax)






9.5% - 10.0%

 

(1) Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases.












(2) Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI.












(3) Represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. The charge also included settlement losses associated with certain foreign pension plans.












(4) Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act).























NM - Not Meaningful











FXN = Foreign Currency Neutral











 

SOURCE BD (Becton, Dickinson and Company)

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Enterprises have forever faced challenges surrounding the sharing of their intellectual property. Emerging cloud adoption has made it more compelling for enterprises to digitize their content, making them available over a wide variety of devices across the Internet. In his session at 19th Cloud Expo, Santosh Ahuja, Director of Architecture at Impiger Technologies, will introduce various mechanisms provided by cloud service providers today to manage and share digital content in a secure manner....
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
StarNet Communications Corp has announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 to safely tunnel the remote desktops from Linux and Unix servers to the user’s PC over encrypted SSH. Traditionally, users of PC X servers deploy the XDMCP protocol to display remote desktop environments such as the Gnome and KDE desktops on Linux servers and the CDE environment on Solaris Unix machines. XDMCP is used primarily on comp...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...